Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Mary Curry

CureSMA, USA

Title: Assessment of awareness of the early clinical features of Spinal Muscular Atrophy (SMA) amongst pediatricians

Biography

Biography: Mary Curry

Abstract

Background: Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by progressive atrophy of the voluntary muscles of the limbs and trunk. The rarity of SMA along with an overlap of early clinical features with other neuromuscular disorders contributes to persistent diagnostic delay that varies from 3.6 months (type I) to 43.6 months (type III); these timeframes overlap with a period of irreversible denervation. Clinical trial data suggests early treatment is critical to modifying the rapid loss of motor neurons while improving life expectancy and clinical outcomes.

Objective: To further understand the diagnostic awareness of SMA amongst general pediatricians as they interact with undiagnosed infants presenting early symptoms.

Methods: The survey was distributed to general pediatricians via email by Medscape Education. The survey was designed to review the clinical decision making of general pediatricians upon observation of hypotonia and/or gross motor delay, as well as overall awareness of the early signs of SMA and neuromuscular disorders.

Results: 300 general pediatricians completed the survey. Upon observation of hypotonia, 55.59% of pediatricians indicated they would immediately refer to early intervention, while 51.64% would immediately refer to a pediatric neurologist for further evaluation. 52.67% correctly indicated that genetic testing is required to make a definitive diagnosis of SMA. Additionally, 70% of respondents indicate comfort identifying the early signs of neuromuscular disease (Extremely comfortable 3.33%; Very comfortable 18.67%; Moderately comfortable 48.33%). Likewise, 67.3% of respondents noted a familiarity with SMA (Extremely familiar 4.33%; Very Familiar 13.67%; Moderately familiar 49.33%), yet of this group, only 59% identified the genetic testing requirement.

Conclusion: This research yielded important insights into current clinical knowledge gaps regarding the diagnosis of SMA and a varied clinical response upon observation of hypotonia amongst pediatricians. Practice guidelines and continuing education may alleviate variation while reducing diagnostic delay.